Clinical Research Associate consultant

Persons authorized to make the requested use or disclosure of this information. The drug sponsor should assure that this disclosure extends to all authorized parties involved in the clinical trial assessment, including Clinical Research Associates, Clinical Research Or-ganizations, other consultants, etc. 

Peter Lacouture, Associate Director, Clinical Research, The Purdue Frederick Company, Norwalk, Connecticut Dr. Fumio Matsumura, Associate Director, Toxic Substances Program, Institute of Toxicology and Environmental Health, University of California, Davis, California Dr. Frederick Oehme, Director, Comparative Toxicology Laboratories, Kansas State University, Manhattan, Kansas and Dr. Jack Radomski, Private Consultant, Jonesport, Maine. These experts collectively have knowledge of heptachlor and heptachlor epoxide s physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended. 

---